News - Shire

Filter

Current filters:

Shire

Popular Filters

1 to 25 of 85 results

Shire’s strong 2nd-qtr financials justify holding out for higher AbbVie bid

Shire’s strong 2nd-qtr financials justify holding out for higher AbbVie bid

18-07-2014

Ireland-headquartered drugmaker Shire, which has just accepted an increased $54 billion bid from the…

AbbVieFinancialIrelandPharmaceuticalShire

Shire finally accepts AbbVie’s takeover offer

Shire finally accepts AbbVie’s takeover offer

18-07-2014

After a protracted and at times hostile courtship, Ireland-headquartered drugmaker Shire has finally…

AbbVieHumiraMergers & AcquisitionsNeurologicalPharmaceuticalRare diseasesShireUSA

Shire succumbs to AbbVie’s yet again increased offer of £53.20 per share

Shire succumbs to AbbVie’s yet again increased offer of £53.20 per share

14-07-2014

Ireland-headquartered Shire, which just on Friday confirmed it had finally entered talks with suitor…

AbbVieAdalimumabFinancialIrelandMergers & AcquisitionsPharmaceuticalShireUSA

Shire confirms it has entered into talks with AbbVie

Shire confirms it has entered into talks with AbbVie

12-07-2014

Following reports by the Bloomberg news service, on Friday Ireland-based drugmaker Shire confirmed that…

AbbVieIrelandMergers & AcquisitionsNeurologicalPharmaceuticalRare diseasesShireUSA

AbbVie comes up with higher offer for Shire of $51.5 billion

AbbVie comes up with higher offer for Shire of $51.5 billion

08-07-2014

As has been widely expected following the meetings last week with major shareholders of Ireland headquartered…

AbbVieMergers & AcquisitionsPharmaceuticalShire

Shire gets positive ruling on Vyvanse patents from US district court

25-06-2014

Ireland-headquartered drugmaker Shire, which is defending itself from a $46 billion unsolicited bid from…

ActavisAmneal PharmaLegalMylanNeurologicalPatentsPharmaceuticalRoxaneSandozShireUSAVyvanse

Analysts view Shire defense as independent pharma

Analysts view Shire defense as independent pharma

24-06-2014

There has been quite a lot of reaction to yesterday’s presentation by Ireland-headquartered Shire's…

AbbVieMergers & AcquisitionsPharmaceuticalShire

Shire sets out robust defense for rejecting AbbVie takeover bid

Shire sets out robust defense for rejecting AbbVie takeover bid

23-06-2014

Ireland-headquartered Shire today presented a robust defense of its position as an independent pharmaceutical…

AbbVieMergers & AcquisitionsPharmaceuticalShire

Charitable pharma companies aim to make a difference

Charitable pharma companies aim to make a difference

20-06-2014

Here's our take on the week's alternative news.

Adderall XRADHDMerck & CoShireVyvanse

Shire rejects unsolicited $46.5 billion takeover offer from AbbVie

Shire rejects unsolicited $46.5 billion takeover offer from AbbVie

20-06-2014

Ireland headquartered Shire has this morning revealed that it has received, and rejected, an unsolicited…

AbbVieMergers & AcquisitionsPharmaceuticalShire

Shire agrees to FDA call for pediatric trials of Vyvanse for ADHD

Shire agrees to FDA call for pediatric trials of Vyvanse for ADHD

12-06-2014

Ireland-headquartered drugmaker Shire says it has agreed to a written request by the US Food and Drug…

NeurologicalPharmaceuticalRegulationResearchShireUSAVyvanse

arGEN-X and Shire sign long term collaboration deal worth $20 million

arGEN-X and Shire sign long term collaboration deal worth $20 million

04-06-2014

Belgium-based preclinical stage biotech firm arGEN-X has entered into a long-term strategic alliance…

arGEN-XBiotechnologyBusiness FinanceEuropeHuman antibody discovery technologiesResearchShireShire Pharmaceuticals

Shire plans NDA filing with FDA for Lifitegrast in 1st-qtr 2015

18-05-2014

Following a May 15, 2014, meeting with the US Food and Drug Administration, Ireland-headquartered drugmaker…

LifitegrastManagementOphthalmicsPharmaceuticalRegulationShire

Shire acquires Lumena Pharma, adding to rare disease portfolio

Shire acquires Lumena Pharma, adding to rare disease portfolio

12-05-2014

Ireland-headquartered drugmaker Shire says it will acquire San Diego, USA-based rare disease focussed…

Lumena PharmaceuticalsMergers & AcquisitionsPharmaceuticalRare diseasesShire

Shire 1st-qrt 2014 sales and earnings rocket; lifitegrast disappoints

01-05-2014

Ireland-headquartered drugmaker Shire posted a strong set of financials this afternoon, showing that…

FinancialLifitegrastOphthalmicsPharmaceuticalRare diseasesResearchShire

Latest EU cost-effectiveness data for epilepsy finds benefits for Shire’s Buccolam

25-04-2014

New European economic modeling data published recently in Health Economics Review provides evidence demonstrating…

BuccolamEuropeFinancialHealthcareNeurologicalPharmaceuticalShire

Actavis prevails in Lialda patent dispute in USA

Actavis prevails in Lialda patent dispute in USA

31-03-2014

US generics major Actavis says that the US Court of Appeals for the Federal Circuit has reversed a lower…

ActavisGastro-intestinalsGenericsLegalLialdaNorth AmericaPatentsShireUSA

UK’s MHRA accepts Shire’s Elvanse filing for ADHD in adults

UK’s MHRA accepts Shire’s Elvanse filing for ADHD in adults

19-02-2014

Ireland-headquartered drugmaker Shire has had an application for its once-daily attention deficit/hyperactivity…

ElvanseNeurologicalPharmaceuticalRegulationShire

Shire CFO Graham Hetherington to step down

Shire CFO Graham Hetherington to step down

13-02-2014

Ireland-headquartered drugmaker Shire (LSE: SHP) has announced that Graham Hetherington, chief financial…

BoardroomNorthern EuropePharmaceuticalShire

Shire posts top year-end results and expects earnings to rise again in 2014

Shire posts top year-end results and expects earnings to rise again in 2014

13-02-2014

Ireland-headquartered drugmaker Shire has recorded a rise in sales and earnings to deliver strong full-year…

DermagraftFinancialFirazyrIntunivLialdaMezavantNorthern EuropePharmaceuticalShireViroPharmaVprivVyvanse

Shire will drop MDD indication for Vyvanse after failed endpoints in Ph III

07-02-2014

Shares of Ireland-headquartered Shire fell 2.4% to £30.67 in early trading, after the company presented…

NeurologicalPharmaceuticalResearchShireVyvanse

Susan Kilsby to succeed Matthew Emmens as chairman of Shire

Susan Kilsby to succeed Matthew Emmens as chairman of Shire

23-01-2014

Ireland-headquartered drugmaker Shire (LSE: SHP) has announced that Susan Kilsby will become non-executive…

BoardroomEuropePharmaceuticalShire

Shire sheds Dermagraft assets for $300 million in milestone payments

Shire sheds Dermagraft assets for $300 million in milestone payments

17-01-2014

Ireland-headquartered drugmaker Shire (LSE: SHP) has agreed to sell its Dermagraft (human fibroblast-derived…

BiotechnologyDermagraftDiabetesLicensingNorthern EuropeShire

1 to 25 of 85 results

Back to top